Diabetologist with a passion for obesity,mental health and patient empowerment.Pilgrim with an Ignatian heart forever thirsty for Christ’s Living Water.
Every human person is planned and willed by God to enter into communion with Him, with others, and with creation. Human dignity does not depend on a person’s abilities, wealth, or position in life, nor on the right or wrong choices made. Instead, it is a gift that precedes and transcends each person, endowed by God as an expression of His unfailing love. #MagnificaHumanitas #GeneralAudience
New @AmerGastroAssn MASLD pathway: for people with type 2 diabetes, you can now skip FIB-4 and go straight to elastography when it’s available.
https://t.co/gb7Mymtotf
A new classification pathway from the 2026 @TheAACE Diabetes Algorithm encourages clinicians to look past a default diagnosis of type 2 and deliberately evaluate for type 1, LADA, MODY, steroid induced diabetes, and other secondary causes whenever the presentation is atypical.
https://t.co/RJm4uwAZYu
🧵The 2026 ACC/AHA Dyslipidemia Guidelines are officially out!
These new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets.
Open access 🔓
https://t.co/NYwsuLQYYz
Here are the most salient features you need to know.👇
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
1.Treat dyslipidemia earlier to reduce lifetime exposure to atherogenic lipoproteins; start lifestyle counseling in youth and consider early pharmacotherapy in high-risk individuals (e.g., familial hypercholesterolemia or LDL-C ≥160 mg/dL).
2.Use the PREVENT™ risk equations instead of older models to estimate 10- and 30-year ASCVD risk in adults aged 30–79, applying the CPR approach: Calculate risk, Personalize assessment, and Reclassify if needed (e.g., with CAC).
3.Consider LDL-lowering therapy in primary prevention starting at a 10-year risk of 3–5%, and recommend it more strongly at 5–10%, after clinician–patient discussion.
4.LDL-C and non-HDL-C targets are reintroduced, while maintaining focus on percentage LDL reduction based on ASCVD risk.
5.Apolipoprotein B (ApoB) measurement can help detect residual lipoprotein-related risk, especially in patients with high triglycerides, diabetes, or low LDL-C.
6.Measure Lipoprotein(a) at least once; elevated levels significantly increase ASCVD risk and warrant more intensive LDL-lowering strategies.
7.Coronary artery calcium (CAC) scoring can refine risk assessment and treatment decisions, particularly in men ≥40 and women ≥45 years.
8.LDL-lowering therapy is recommended for adults aged 40–75 with diabetes, CKD stage 3–4, or HIV regardless of LDL-C level.
https://t.co/WEvDXJyoJz secondary prevention, stricter targets are recommended: LDL-C <55 mg/dL and non-HDL-C <85 mg/dL for very high-risk patients.
10.Statins remain the foundation of therapy, particularly in patients with elevated triglycerides; additional therapies may be needed for severe hypertriglyceridemia to prevent pancreatitis.
#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@JACCJournals@ACCinTouch@DLBHATTMD@CMichaelGibson@DrMarthaGulati@hvanspall@AndrewJSauer@ESC_Journals@escardio
https://t.co/Sc1gGv1p6y
1/9
The 2026 ACC/AHA Dyslipidemia Guidelines are officially here!
Replacing the 2018 guidelines, these new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets.
Here are the most salient features you need to know. 🧵👇
#Cardiology #MedTwitter
Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression - eClinicalMedicine https://t.co/3kSZruFyv3
👏Congratulations to @ObesitySociety@ObesityAction@OMAsocial on their Expert Guidance Statement on #obesity pharmacotherapy
👉https://t.co/6xUXZieyUB
It has been a long road since the 2013 guidelines, so this gives us a much needed update to medical #weightmanagement and further cements the consensus among several professional societies to
1. Treat obesity as a disease
2. Prioritize patient-centered care
3. Commit to evidence-based #medicine
And thank you to #ObesityJournal for the opportunity to author an accompanying editorial with Dr Donna Ryan
👉https://t.co/NWrFj37av7
GLP-1 in type 1 diabetes #EASD2025 the crowd at spotlight session show the interest in this area which os evolving with trials due to reports and perhaps a change of license
⚙️🧬 The Twin Cycle: Type 2’s Hidden Gears of Reversal
🔹 Liver & pancreas fat drive #T2D onset via self-reinforcing cycles
🔸 15kg weight loss = ⤵️ fat, ⤴️ insulin secretion, and reversal
🔹 DiRECT & ReTUNE confirm remission is durable—even in lean BMI
🔸 Beta cells don’t fail—they’re silenced by fat
👉 #T2D is reversible in many—if you turn the right gears❗️
🔗https://t.co/zqgaVHGriW
Oh how beautiful our universal Church is 🥹
To think that 2,000 years ago in this very spot, our first Pope Peter was brutally crucified & martyred for his faith, & now over 1.4 billion people rejoice at our 267th Pope is so humbling 🇻🇦🕊
VATICAN CITY—Today is the Feast of St Michael the Archangel (his apparition in Italy)
Pope Leo XIII wrote the exorcism prayer to St Michael the Archangel.
Now, Pope Leo XIV exclaims, “God desires our good! God loves all of us! Evil will not Prevail!”
As we wait for a new pope to be announced, I feel bittersweet. I am so happy we have a shepherd again, but turning the page on Pope Francis is hard.
Well done, good and faithful servant.
Where Christians are "mocked, opposed, despised or at best tolerated and pitied" is where the Catholic Church's "missionary outreach is most desperately needed," Pope Leo XIV said in his first homily as leader of the world's 1.4 billion Catholics.
« God cares for us, God loves all of us, and evil will not prevail ! We are all in God's hands. Therefore, without fear, united hand in hand with God and among ourselves, let us move forward. »